TY - STD TI - Haberland J, Bertz J, Wolf U, Ziese T, Kurth BM. German cancer statistics 2004. BMC Cancer. 2010;10:52. ID - ref1 ER - TY - JOUR AU - Jemal, A. AU - Siegel, R. AU - Xu, J. AU - Ward, E. PY - 2010 DA - 2010// TI - Cancer statistics, 2010 JO - CA Cancer J Clin VL - 60 UR - https://doi.org/10.3322/caac.20073 DO - 10.3322/caac.20073 ID - Jemal2010 ER - TY - JOUR AU - Conroy, T. AU - Desseigne, F. AU - Ychou, M. AU - Bouche, O. AU - Guimbaud, R. AU - Becouarn, Y. PY - 2011 DA - 2011// TI - FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer JO - N Engl J Med. VL - 364 UR - https://doi.org/10.1056/NEJMoa1011923 DO - 10.1056/NEJMoa1011923 ID - Conroy2011 ER - TY - JOUR AU - Hoff, D. D. AU - Ervin, T. AU - Arena, F. P. AU - Chiorean, E. G. AU - Infante, J. AU - Moore, M. PY - 2013 DA - 2013// TI - Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine JO - N Engl J Med. VL - 369 UR - https://doi.org/10.1056/NEJMoa1304369 DO - 10.1056/NEJMoa1304369 ID - Hoff2013 ER - TY - STD TI - Rahma OE, Duffy A, Liewehr DJ, Steinberg SM, Greten TF. Second-line treatment in advanced pancreatic cancer: a comprehensive analysis of published clinical trials. Ann Oncol. 2013. ID - ref5 ER - TY - JOUR AU - Cid-Arregui, A. AU - Juarez, V. PY - 2015 DA - 2015// TI - Perspectives in the treatment of pancreatic adenocarcinoma JO - World J Gastroenterol VL - 21 UR - https://doi.org/10.3748/wjg.v21.i31.9297 DO - 10.3748/wjg.v21.i31.9297 ID - Cid-Arregui2015 ER - TY - STD TI - Gresham GK, Wells GA, Gill S, Cameron C, Jonker DJ. Chemotherapy regimens for advanced pancreatic cancer: a systematic review and network meta-analysis. BMC Cancer. 2014;14:471. ID - ref7 ER - TY - STD TI - Pelzer U, Schwaner I, Stieler J, Adler M, Seraphin J, Dorken B, et al. Best supportive care (BSC) versus oxaliplatin, folinic acid and 5-fluorouracil (OFF) plus BSC in patients for second-line advanced pancreatic cancer: a phase III-study from the German CONKO-study group. Eur J Cancer. 2011;47:1676–81. ID - ref8 ER - TY - STD TI - Oettle H, Riess H, Stieler JM, Heil G, Schwaner I, Seraphin J, et al. Second-line oxaliplatin, folinic acid, and fluorouracil versus folinic acid and fluorouracil alone for gemcitabine-refractory pancreatic cancer: outcomes from the CONKO-003 trial. J Clin Oncol. 2014;32:2423–9. ID - ref9 ER - TY - STD TI - Wang-Gillam A, Li CP, Bodoky G, Dean A, Shan YS, Jameson G, et al. Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial. Lancet. 2015 Nov 29, [Epub ahead of print] ID - ref10 ER - TY - STD TI - Kim ST, Choi YJ, Park KH, Oh SC, Seo JH, Shin SW, et al. A prognostic model to identify patients with advanced pancreas adenocarcinoma who could benefit from second-line chemotherapy. Clin Oncol (R Coll Radiol). 2012;24:105–11. ID - ref11 ER - TY - JOUR AU - Lenzi, R. AU - Yalcin, S. AU - Evans, D. B. AU - Abbruzzese, J. L. PY - 2002 DA - 2002// TI - Phase II study of docetaxel in patients with pancreatic cancer previously untreated with cytotoxic chemotherapy JO - Cancer Invest VL - 20 UR - https://doi.org/10.1081/CNV-120002146 DO - 10.1081/CNV-120002146 ID - Lenzi2002 ER - TY - STD TI - Rougier P, Adenis A, Ducreux M, de Forni M, Bonneterre J, Dembak M, et al. A phase II study: docetaxel as first-line chemotherapy for advanced pancreatic adenocarcinoma. Eur J Cancer. 2000;36:1016–25. ID - ref13 ER - TY - JOUR AU - Cereda, S. AU - Reni, M. PY - 2008 DA - 2008// TI - Weekly docetaxel as salvage therapy in patients with gemcitabine-refractory metastatic pancreatic cancer JO - J Chemother VL - 20 UR - https://doi.org/10.1179/joc.2008.20.4.509 DO - 10.1179/joc.2008.20.4.509 ID - Cereda2008 ER - TY - JOUR AU - Saif, M. W. AU - Syrigos, K. AU - Penney, R. AU - Kaley, K. PY - 2010 DA - 2010// TI - Docetaxel second-line therapy in patients with advanced pancreatic cancer: a retrospective study JO - Anticancer Res VL - 30 ID - Saif2010 ER - TY - STD TI - Berk V, Ozdemir N, Ozkan M, Aksoy S, Turan N, Inal A, et al. XELOX vs. FOLFOX4 as second line chemotherapy in advanced pancreatic cancer. Hepatogastroenterology. 2012;59:2635–9. ID - ref16 ER - TY - JOUR AU - El-Hadaad, H. A. AU - Wahba, H. A. PY - 2013 DA - 2013// TI - Oxaliplatin plus 5-fluorouracil and folinic acid (OFF) in gemcitabine-pretreated advanced pancreatic cancer: a phase II study JO - J Gastrointest Cancer VL - 44 UR - https://doi.org/10.1007/s12029-013-9495-5 DO - 10.1007/s12029-013-9495-5 ID - El-Hadaad2013 ER - TY - STD TI - Zaniboni A, Aitini E, Barni S, Ferrari D, Cascinu S, Catalano V, et al. FOLFIRI as second-line chemotherapy for advanced pancreatic cancer: a GISCAD multicenter phase II study. Cancer Chemother Pharmacol. 2012;69:1641–5. ID - ref18 ER - TY - STD TI - Kouroussis C, Agelaki S, Mavroudis D, Kakolyris S, Androulakis N, Kalbakis K, et al. A dose escalation study of docetaxel and oxaliplatin combination in patients with metastatic breast and non-small cell lung cancer. Anticancer Res. 2003;23:785–91. ID - ref19 ER - TY - STD TI - Raez LE, Santos ES, Lopes G, Rosado MF, Negret LM, Rocha-Lima C, et al. Efficacy and safety of oxaliplatin and docetaxel in patients with locally advanced and metastatic non-small-cell lung cancer (NSCLC). Lung Cancer. 2006;53:347–53. ID - ref20 ER - TY - STD TI - Richards D, Kocs DM, Spira AI, David McCollum A, Diab S, Hecker LI, et al. Results of docetaxel plus oxaliplatin (DOCOX) +/− cetuximab in patients with metastatic gastric and/or gastroesophageal junction adenocarcinoma: results of a randomised Phase 2 study. Eur J Cancer. 2013;49:2823–31. ID - ref21 ER - TY - STD TI - NCT00690300. Docetaxel plus Oxaliplatin as Therapy in Patients With Pancreatic Cancer. ClinicalTrials.gov 2008. ID - ref22 ER - TY - JOUR AU - Simon, R. PY - 1989 DA - 1989// TI - Optimal two-stage designs for phase II clinical trials JO - Control Clin Trials VL - 10 UR - https://doi.org/10.1016/0197-2456(89)90015-9 DO - 10.1016/0197-2456(89)90015-9 ID - Simon1989 ER - TY - STD TI - Burris 3rd HA, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol. 1997;15:2403–13. ID - ref24 ER - TY - STD TI - Bonnetain F, Dahan L, Maillard E, Ychou M, Mitry E, Hammel P, et al. Time until definitive quality of life score deterioration as a means of longitudinal analysis for treatment trials in patients with metastatic pancreatic adenocarcinoma. Eur J Cancer. 2010;46:2753–62. ID - ref25 ER - TY - STD TI - Anota A, Hamidou Z, Paget-Bailly S, Chibaudel B, Bascoul-Mollevi C, Auquier P, et al. Time to health-related quality of life score deterioration as a modality of longitudinal analysis for health-related quality of life studies in oncology: do we need RECIST for quality of life to achieve standardization? Qual Life Res. 2015;24:5–18. ID - ref26 ER - TY - STD TI - Ko AH, Tempero MA, Shan YS, Su WC, Lin YL, Dito E, et al. A multinational phase 2 study of nanoliposomal irinotecan sucrosofate (PEP02, MM-398) for patients with gemcitabine-refractory metastatic pancreatic cancer. Br J Cancer. 2013;109:920–5. ID - ref27 ER - TY - STD TI - Yoo C, Hwang JY, Kim JE, Kim TW, Lee JS, Park DH, et al. A randomised phase II study of modified FOLFIRI.3 vs modified FOLFOX as second-line therapy in patients with gemcitabine-refractory advanced pancreatic cancer. Br J Cancer. 2009;101:1658–63. ID - ref28 ER - TY - STD TI - Grothey A, Nikcevich DA, Sloan JA, Kugler JW, Silberstein PT, Dentchev T, et al. Intravenous calcium and magnesium for oxaliplatin-induced sensory neurotoxicity in adjuvant colon cancer: NCCTG N04C7. J Clin Oncol. 2011;29:421–7. ID - ref29 ER - TY - STD TI - Loprinzi CL, Qin R, Dakhil SR, Fehrenbacher L, Flynn KA, Atherton P, et al. Phase III randomized, placebo-controlled, double-blind study of intravenous calcium and magnesium to prevent oxaliplatin-induced sensory neurotoxicity (N08CB/Alliance). J Clin Oncol. 2014;32:997–1005. ID - ref30 ER - TY - STD TI - Hosein PJ, de Lima Lopes G, Jr., Pastorini VH, Gomez C, Macintyre J, Zayas G, et al. A phase II trial of nab-Paclitaxel as second-line therapy in patients with advanced pancreatic cancer. Am J Clin Oncol. 2013 Apr; 36(2):151-6. ID - ref31 ER - TY - STD TI - Assaf E, Verlinde-Carvalho M, Delbaldo C, Grenier J, Sellam Z, Pouessel D, et al. 5-fluorouracil/leucovorin combined with irinotecan and oxaliplatin (FOLFIRINOX) as second-line chemotherapy in patients with metastatic pancreatic adenocarcinoma. Oncology. 2011;80:301–6. ID - ref32 ER - TY - STD TI - Lee MG, Lee SH, Lee SJ, Lee YS, Hwang JH, Ryu JK, et al. 5-Fluorouracil/leucovorin combined with irinotecan and oxaliplatin (FOLFIRINOX) as second-line chemotherapy in patients with advanced pancreatic cancer who have progressed on gemcitabine-based therapy. Chemotherapy. 2013;59:273–9. ID - ref33 ER - TY - STD TI - Soares HP, Bayraktar S, Blaya M, Lopes G, Merchan J, Macintyre J, et al. A phase II study of capecitabine plus docetaxel in gemcitabine-pretreated metastatic pancreatic cancer patients: CapTere. Cancer Chemother Pharmacol. 2014;73:839–45. ID - ref34 ER - TY - STD TI - Xiong HQ, Varadhachary GR, Blais JC, Hess KR, Abbruzzese JL, Wolff RA. Phase 2 trial of oxaliplatin plus capecitabine (XELOX) as second-line therapy for patients with advanced pancreatic cancer. Cancer. 2008;113:2046–52. ID - ref35 ER - TY - STD TI - Demols A, Peeters M, Polus M, Marechal R, Gay F, Monsaert E, et al. Gemcitabine and oxaliplatin (GEMOX) in gemcitabine refractory advanced pancreatic adenocarcinoma: a phase II study. Br J Cancer. 2006;94:481–5. ID - ref36 ER - TY - STD TI - Dragovich T, Laheru D, Dayyani F, Bolejack V, Smith L, Seng J, et al. Phase II trial of vatalanib in patients with advanced or metastatic pancreatic adenocarcinoma after first-line gemcitabine therapy (PCRT O4-001). Cancer Chemother Pharmacol. 2014;74:379–87. ID - ref37 ER -